Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. In this phase II study, 14 patients with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m(2)/day as 4...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Albertini, Mark R., Hank, Jacquelyn A., Gadbaw, Brian, Kostlevy, Jordan, Haldeman, Jennifer, Schalch, Heidi, Gan, Jacek, Kim, KyungMann, Eickhoff, Jens, Gillies, Stephen D., Sondel, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer-Verlag 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502633/
https://ncbi.nlm.nih.gov/pubmed/22678096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1286-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados